Is Femasys Inc. (FEMY) a Buy, Sell, or Hold?
NASDAQ : FEMY
Femasys Inc.
$3.57 USD
-$0.03 (-0.83%)
- Volume
- 10.76K
- Average Volume
- 62.04K
- Market Capitalization
- $10.78M
- P/E Ratio
- -0.56
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $22.20
- Year Low
- $3.39
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $3.91
NUMBER OF INSIDERS BUYING (LAST 12 MONTHS)
36
NUMBER OF INSIDERS SELLING (LAST 12 MONTHS)
0
AMOUNT OF INSIDER SELLING (LAST 12 MONTHS)
-$
FEMY Estimated and Actual Revenue by Quarter
Get MSFT Insider Trade Alerts
FEMY Insider Trading History
| Insider Name | Title | Date | Transaction | Cost | Filing Date |
|---|---|---|---|---|---|
| Canning John Charles | officer: Chief Operating Officer | 2026-03-30 | A-Award | 0.38 | 2026-04-01 |
| Canning John Charles | officer: Chief Operating Officer | 2026-03-30 | 0 | 2026-04-01 | |
| Lee-Sepsick Kathy | director, officer: Chief Executive Officer | 2026-03-19 | A-Award | 0.58 | 2026-03-27 |
| Elefant Dov | officer: Chief Financial Officer | 2026-03-19 | A-Award | 0.58 | 2026-03-27 |
| Eichenbaum Kenneth D. | director | 2026-03-19 | A-Award | 0.58 | 2026-03-27 |
| Larsen Charles | director | 2026-03-19 | A-Award | 0.58 | 2026-03-27 |
| Eichenbaum Kenneth D. | director | 2026-03-18 | 0 | 2026-03-24 | |
| Eichenbaum Kenneth D. | director | 2025-11-07 | 0.81 | 2026-03-24 | |
| Eichenbaum Kenneth D. | director | 2025-11-07 | 0.73 | 2026-03-24 | |
| Eichenbaum Kenneth D. | director | 2025-11-07 | 0.92 | 2026-03-24 | |
| Eichenbaum Kenneth D. | director | 2025-11-07 | 1.1 | 2026-03-24 | |
| Eichenbaum Kenneth D. | director | 2026-03-18 | A-Award | 0.6 | 2026-03-20 |
| PharmaCyte Biotech, Inc. | 10 percent owner: | 2026-03-17 | 0 | 2026-03-18 | |
| Silverman Joshua | director: | 2026-03-17 | 0 | 2026-03-18 | |
| Lee-Sepsick Kathy | director, officer: Chief Executive Officer | 2026-02-19 | A-Award | 0 | 2026-02-20 |
| Lee-Sepsick Kathy | director, officer: Chief Executive Officer | 2026-02-19 | A-Award | 0 | 2026-02-20 |
| Elefant Dov | officer: Chief Financial Officer | 2026-02-19 | A-Award | 0 | 2026-02-20 |
| Elefant Dov | officer: Chief Financial Officer | 2026-02-19 | A-Award | 0 | 2026-02-20 |
| Sipos Jeremy Alexander | officer: Chief Technology Officer | 2026-02-02 | A-Award | 0 | 2026-02-17 |
| Sipos Jeremy Alexander | officer: Chief Technology Officer | 2025-12-16 | 0 | 2026-02-17 | |
| Sipos Jeremy Alexander | officer: Chief Technology Officer | 2025-12-16 | 3 | 2026-02-17 | |
| Sipos Jeremy Alexander | officer: Chief Technology Officer | 2025-12-16 | 0.87 | 2026-02-17 | |
| Sipos Jeremy Alexander | officer: Chief Technology Officer | 2025-12-16 | 0.8 | 2026-02-17 | |
| Sipos Jeremy Alexander | officer: Chief Technology Officer | 2025-12-16 | 1.05 | 2026-02-17 | |
| Sipos Jeremy Alexander | officer: Chief Technology Officer | 2025-12-16 | 3.24 | 2026-02-17 | |
| Sipos Jeremy Alexander | officer: Chief Technology Officer | 2025-12-16 | 6.12 | 2026-02-17 | |
| Lee-Sepsick Kathy | director, officer: Chief Executive Officer | 2025-11-07 | I-Discretionary | 0.81 | 2025-11-19 |
| Lee-Sepsick Kathy | director, officer: Chief Executive Officer | 2025-11-07 | I-Discretionary | 1.1 | 2025-11-19 |
| Lee-Sepsick Kathy | director, officer: Chief Executive Officer | 2025-11-07 | I-Discretionary | 0.92 | 2025-11-19 |
| Lee-Sepsick Kathy | director, officer: Chief Executive Officer | 2025-11-07 | I-Discretionary | 0.73 | 2025-11-19 |
| Larsen Charles | director | 2025-11-07 | I-Discretionary | 1.1 | 2025-11-12 |
| Larsen Charles | director | 2025-11-07 | I-Discretionary | 0.92 | 2025-11-12 |
| Larsen Charles | director | 2025-11-07 | I-Discretionary | 0.81 | 2025-11-12 |
| Larsen Charles | director | 2025-11-07 | I-Discretionary | 0.73 | 2025-11-12 |
| Elefant Dov | officer: Chief Financial Officer | 2025-11-07 | I-Discretionary | 0.81 | 2025-11-12 |
| Elefant Dov | officer: Chief Financial Officer | 2025-11-07 | I-Discretionary | 1.1 | 2025-11-12 |
| Elefant Dov | officer: Chief Financial Officer | 2025-11-07 | I-Discretionary | 0.92 | 2025-11-12 |
| Elefant Dov | officer: Chief Financial Officer | 2025-11-07 | I-Discretionary | 0.73 | 2025-11-12 |
| Elefant Dov | officer: Chief Financial Officer | 2025-08-27 | I-Discretionary | 0.5151 | 2025-08-28 |
| Elefant Dov | officer: Chief Financial Officer | 2025-08-27 | I-Discretionary | 0.5151 | 2025-08-28 |
| Lee-Sepsick Kathy | director, officer: Chief Executive Officer | 2025-08-27 | I-Discretionary | 0.5151 | 2025-08-28 |
| Lee-Sepsick Kathy | director, officer: Chief Executive Officer | 2025-08-27 | I-Discretionary | 0.5151 | 2025-08-28 |
| Nicholas Kelley Stinson | officer: Chief Commercial Officer | 2025-06-23 | A-Award | 0.9 | 2025-07-01 |
| Nicholas Kelley Stinson | officer: Chief Commercial Officer | 2025-06-23 | 0 | 2025-07-01 | |
| Nicholas Kelley Stinson | officer: Chief Commercial Officer | 2025-06-23 | 0 | 2025-07-01 | |
| Uzialko Edward R | director | 2025-06-25 | A-Award | 0.98 | 2025-06-27 |
| Milnes Alistair | director | 2025-06-25 | A-Award | 0.98 | 2025-06-27 |
| Larsen Charles | director | 2025-06-25 | A-Award | 0.98 | 2025-06-27 |
| Silverman Joshua | director | 2025-06-25 | A-Award | 0.98 | 2025-06-27 |
| Larsen Charles | director | 2025-06-02 | I-Discretionary | 1.02 | 2025-06-04 |
| Currie Daniel Scott | officer: Chief Operating Officer | 2025-06-02 | I-Discretionary | 1.02 | 2025-06-04 |
| Elefant Dov | officer: Chief Financial Officer | 2025-06-02 | I-Discretionary | 1.02 | 2025-06-04 |
| Lee-Sepsick Kathy | director, officer: Chief Executive Officer | 2025-06-02 | I-Discretionary | 1.02 | 2025-06-04 |
| Currie Daniel Scott | officer: Chief Operating Officer | 2025-01-28 | A-Award | 1.05 | 2025-01-30 |
| Currie Daniel Scott | officer: Chief Operating Officer | 2025-01-28 | A-Award | 1.05 | 2025-01-30 |
| Currie Daniel Scott | officer: Chief Operating Officer | 2025-01-28 | A-Award | 1.05 | 2025-01-30 |
| Thomas Christine E | officer: Chief Reg & Clinical Officer | 2025-01-28 | A-Award | 1.05 | 2025-01-30 |
| Thomas Christine E | officer: Chief Reg & Clinical Officer | 2025-01-28 | A-Award | 1.05 | 2025-01-30 |
| Thomas Christine E | officer: Chief Reg & Clinical Officer | 2025-01-28 | A-Award | 1.05 | 2025-01-30 |
| Elefant Dov | officer: Chief Financial Officer | 2025-01-28 | A-Award | 1.05 | 2025-01-30 |
| Elefant Dov | officer: Chief Financial Officer | 2025-01-28 | A-Award | 1.05 | 2025-01-30 |
| Lee-Sepsick Kathy | director, officer: Chief Executive Officer | 2025-01-29 | A-Award | 1.17 | 2025-01-30 |
| Lee-Sepsick Kathy | director, officer: Chief Executive Officer | 2025-01-29 | A-Award | 1.17 | 2025-01-30 |
| Lee-Sepsick Kathy | director, officer: Chief Executive Officer | 2025-01-29 | A-Award | 1.17 | 2025-01-30 |
| Silverman Joshua | director | 2024-07-12 | A-Award | 1.14 | 2024-07-15 |
| Larsen Charles | director | 2024-07-12 | A-Award | 1.14 | 2024-07-15 |
| Milnes Alistair | director | 2024-07-12 | A-Award | 1.14 | 2024-07-15 |
| Uzialko Edward R | director | 2024-07-12 | A-Award | 1.14 | 2024-07-15 |
| Spector Richard D. | officer: Chief Commercial Officer | 2024-02-12 | A-Award | 1.1 | 2024-02-13 |
| Spector Richard D. | 2024-02-12 | 0 | 2024-02-13 | ||
| Currie Daniel Scott | officer: Chief Operating Officer | 2024-02-01 | A-Award | 0.8 | 2024-02-02 |
| Elefant Dov | officer: Chief Financial Officer | 2024-02-01 | A-Award | 0.8 | 2024-02-02 |
| Thomas Christine E | officer: SVP, Regulatory & Clinical | 2024-02-01 | A-Award | 0.8 | 2024-02-02 |
| Lee-Sepsick Kathy | director, officer: Chief Executive Officer | 2024-02-01 | A-Award | 0.8 | 2024-02-02 |
| PharmaCyte Biotech, Inc. | 10 percent owner | 2023-11-21 | 1.18 | 2023-11-28 | |
| PharmaCyte Biotech, Inc. | 10 percent owner | 2023-11-21 | 1.18 | 2023-11-28 | |
| PharmaCyte Biotech, Inc. | 10 percent owner | 2023-11-21 | 1.475 | 2023-11-28 | |
| Silverman Joshua | director | 2023-11-21 | A-Award | 0.9 | 2023-11-22 |
| Silverman Joshua | 2023-11-21 | 0 | 2023-11-22 | ||
| Thomas Christine E | officer: SVP, Regulatory & Clinical | 2023-10-10 | A-Award | 1.76 | 2023-11-01 |
| Lee-Sepsick Kathy | director, officer: Chief Executive Officer | 2023-07-03 | A-Award | 0.49 | 2023-07-03 |
| Lee-Sepsick Kathy | director, officer: Chief Executive Officer | 2023-07-03 | A-Award | 0.49 | 2023-07-03 |
| Elefant Dov | officer: Chief Financial Officer | 2023-07-03 | A-Award | 0.49 | 2023-07-03 |
| Elefant Dov | officer: Chief Financial Officer | 2023-07-03 | A-Award | 0.49 | 2023-07-03 |
| Currie Daniel Scott | officer: Senior VP, Operations | 2023-07-03 | A-Award | 0.49 | 2023-07-03 |
| Currie Daniel Scott | officer: Senior VP, Operations | 2023-07-03 | A-Award | 0.49 | 2023-07-03 |
| Morrissey Anne | director | 2023-06-21 | A-Award | 0.57 | 2023-06-23 |
| Perrow Wendy | director | 2023-06-21 | A-Award | 0.57 | 2023-06-23 |
| Larsen Charles | director | 2023-06-21 | A-Award | 0.57 | 2023-06-23 |
| Uzialko Edward R | director | 2023-06-21 | A-Award | 0.57 | 2023-06-23 |
| Milnes Alistair | director | 2023-06-14 | A-Award | 0.64 | 2023-06-16 |
| Kendall Keith J | director | 2023-06-14 | A-Award | 0.64 | 2023-06-16 |
| Milnes Alistair | 2023-06-14 | 0 | 2023-06-16 | ||
| Kendall Keith J | 2023-06-14 | 0 | 2023-06-16 | ||
| Thomas Christine E | director: SVP, Regulatory & Clinical | 2022-10-10 | A-Award | 0 | 2022-10-17 |
| Thomas Christine E | None | 2022-10-10 | None | 2022-10-17 | |
| Thomas Christine E | 2022-10-10 | 0 | 2022-10-17 | ||
| Dyett John | director: | 2022-06-08 | A-Award | 0 | 2022-06-10 |
| Perrow Wendy | director | 2022-06-08 | A-Award | 1.5 | 2022-06-10 |
| Perrow Wendy | director: | 2022-06-08 | A-Award | 0 | 2022-06-10 |